Entera Bio Ltd. (ENTX) Reports Q1 Loss of $0.16
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Wall Street sinks as Nasdaq falls over 2% on AI cost worries
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Entera Bio Ltd Announces Interim Biomarker Data From Phase 2 Clinical Trial of EB613 and First Quarter 2020 Financial Results
May 21, 2020 6:30 AM EDTStatistically Significant One Month Increases in P1NP Biomarker from First 50% of Patients with Highest Dose of EB613 Company to Follow Patients in the Phase 2 Clinical Trial of EB613 through Six Months for Bone Mineral Density Data and Evaluate Additional Higher Doses of EB613... More



